Article Listing - BioTime acquires Geron's stem cell program
Amgen's trebananib meets primary end-point in Ph III study of recurrent ovarian cancer
13 June 2013
USA-based Amgen (Nasdaq: AMGN), the world's largest independent biotech firm, has announced that the Phase III TRINOVA-1 trial evaluating trebananib (AMG 386) plus paclitaxel versus placebo plus paclitaxel in recurrent ovarian cancer met its primary endpoint of progression-free survival (PFS).
First approved new class of IBS-C therapy, Constella, now available in Europe
13 June 2013
Spain's largest drugmaker Almirall (ALM: MC) and US partner Ironwood Pharmaceuticals, (Nasdaq: IRWD) today (June 13) announced the launch of Constella (linaclotide 290mcg capsules once daily), the first approved prescription therapy in a new class of treatments for adults suffering from moderate to severe IBS-C, in Europe. Constella is now available in Germany, the UK and Nordic countries and is expected to be launched in several other European countries in 2013.
Rising drug resistance driving early-line use of powerful antibiotics, according to surveyed EU5 physicians
13 June 2013
More than half of physicians surveyed by health care advisory firm, Decision Resources from the EU5 (France, Germany, Italy, Spain and the UK) prescribe carbapenems, especially meropenem (Cubist/AstraZeneca's Merrem/Meronem; Dainippon Sumitomo's Meropen; generics) and imipenem/cilastatin (Merck's Primaxin/Tienam; generics), as first- or second-line therapy for Gram-negative infections (GNIs) due to ESBL-producing Enterobacteriaceae.
Generics triple-therapy just as effective as brand-name Enbrel, new study shows
13 June 2013
Global biotech leader Amgen's (Nasdaq: AMGN) branded drug Enbrel (etanercept) is no more effective in treating rheumatoid arthritis than cheaper generic drugs, according to new research published in the Journal of the Medical Association, funded by the US Department of Veteran Affairs.
Teva and Active Biotech to move forward with laquinimod on positive Ph IIa results in active lupus nephritis
13 June 2013
Israel's Teva Pharmaceutical Industries (NYSE: TEVA) and Swedish partner Active Biotech (OMX NORDIC: ACTI) have released positive results of a Phase IIa study of oral laquinimod designed to assess safety, tolerability and clinical efficacy in patients with active lupus nephritis, one of the most serious manifestations of systemic lupus erythematosus (SLE or lupus) that can lead to chronic kidney failure.
Over 200 novel drugs in development for heart disease and stroke, says PhRMA
13 June 2013
America's biopharmaceutical research companies are developing 215 medicines for two of the leading causes of death of Americans - heart disease and stroke, according to a new report and overview released yesterday (June 12) by the Pharmaceutical Research and Manufacturers of America (PhRMA).
NICE final draft guidance on Eli Lilly's Alimta negative
13 June 2013
UK drugs watch dog the National Institute for Health and Care Excellence (NICE) this morning (June 13) issued final draft guidance not recommending US drug major Eli Lilly's Alimta (pemetrexed) for the maintenance treatment of non-small-cell lung cancer (NSCLC) following induction therapy with pemetrexed and cisplatin.
Pfizer in $2.15 billion settlement from Teva and Sun for infringement of Protonix patent
12 June 2013
Global pharma behemoth Pfizer (NYSE: PFE) today (June 12) said it has reached a $2.15 billion settlement reached with Israel-based Teva Pharmaceuticals Industries (NYSE: TEVA) and India's Sun Pharmaceutical Industries (SUNP: IN) for patent-infringement damages resulting from their "at-risk" launches of generic Protonix (pantoprazole) in the USA.
American Diabetes Association calls for independent review of incretin-based therapy
12 June 2013
The American Diabetes Association is asking all pharmaceutical companies involved in the development or marketing of incretin-based medications, used to lower blood glucose levels, to make patient-level data on their products available for an independent review that could help settle the question of whether such therapies contribute to the development of pancreatitis or pancreatic cancer.
Amgen and Cytokinetics expand omecamtiv mecarbil accord
12 June 2013
USA-based Amgen (Nasdaq: AMGN), the world's largest independent biotech company, has expanded its strategic collaboration with Cytokinetics (Nasdaq: CYTK) to include Japan. In 2006, Cytokinetics and Amgen entered into a collaboration to discover, develop and commercialize novel small-molecule therapeutics that activate cardiac muscle contractility for potential applications in the treatment of heart failure.
- FDA probes two deaths possibly linked to Lilly's antipsychotic Zyprexa Relprevv
- US Supreme Court says patent settlement can "sometimes" be illegal
- Negative US patent ruling for Novo Nordisk on Prandin
- Daiichi Sankyo files for Japanese approval of Prasugrel
- Osteoporosis drug bazedoxifene stops growth of breast cancer cells, even in resistant tumors
